CEA (carcinoembryonic antigen) and CYFRA (cytokeratin 19 fragment) are elevated in sera in a subset of lung cancer patients, and are clinically applied to monitor the disease status and evaluate the response to treatments. This evidence concerns the gene CEACAM5 and lung carcinoma.